Lotus Pharmaceutical Co., Ltd. Statistics
Lotus Pharmaceutical Co., Ltd. (1795) Stock Statistics & Valuation Metrics
Total Valuation
Lotus Pharmaceutical Co., Ltd. has a market cap or net worth of TWD 44.15B. The enterprise value is TWD 102.18B.
- Market Cap
- TWD 44.15B
- Enterprise Value
- TWD 102.18B
Share Statistics
Lotus Pharmaceutical Co., Ltd. has 270,035,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 270,035,250
- Owned by Insiders
- ―
- Owned by Institutions
- 3.16%
Financial Efficiency
Lotus Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 5.20%.
- Return on Equity (ROE)
- 0.20
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- 5.20%
- Return on Capital Employed (ROCE)
- 0.07
- Revenue Per Employee
- 18.66M
- Profits Per Employee
- 4.29M
- Employee Count
- 1,099
- Asset Turnover
- 0.19
- Inventory Turnover
- 1.02
Valuation Ratios
The current PE Ratio of Lotus Pharmaceutical Co., Ltd. is 11.52. Lotus Pharmaceutical Co., Ltd.’s PEG ratio is -0.52.
- PE Ratio
- 11.52
- PS Ratio
- 1.55
- PB Ratio
- 1.78
- Price to FCF
- 16.97
- Price to Operating Cash Flow
- 9.61
- PEG Ratio
- -0.52
Income Statement
In the last 12 months, Lotus Pharmaceutical Co., Ltd. had revenue of 20.51B and earned 4.72B in profits. Earnings per share was 18.14.
- Revenue
- 20.51B
- Gross Profit
- 10.64B
- Operating Income
- 5.90B
- Pretax Income
- 5.72B
- Net Income
- 4.72B
- EBITDA
- 7.44B
- Earnings Per Share (EPS)
- 18.14
Cash Flow
In the last 12 months, operating cash flow was 4.50B and capital expenditures -1.90B, giving a free cash flow of 2.61B billion.
- Operating Cash Flow
- 4.50B
- Free Cash Flow
- 2.61B
- Free Cash Flow per Share
- 10.03
Dividends & Yields
Lotus Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 1.55%
- Dividend Per Share
- ―
- Dividend Yield
- 1.55%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 5.89%
- Earnings Yield
- 8.70%
Stock Price Statistics
- Beta
- 0.43
- 52-Week Price Change
- -41.00%
- 50-Day Moving Average
- 176.38
- 200-Day Moving Average
- 205.60
- Relative Strength Index (RSI)
- 40.52
- Average Volume (3m)
- 1.03M
Important Dates
Lotus Pharmaceutical Co., Ltd. upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Lotus Pharmaceutical Co., Ltd. as a current ratio of 1.57, with Debt / Equity ratio of 235.22%
- Current Ratio
- 1.57
- Quick Ratio
- 1.00
- Debt to Market Cap
- 0.75
- Net Debt to EBITDA
- 6.48
- Interest Coverage Ratio
- 6.59
Taxes
In the past 12 months, Lotus Pharmaceutical Co., Ltd. has paid 998.12M in taxes.
- Income Tax
- 998.12M
- Effective Tax Rate
- 0.17
Enterprise Valuation
Lotus Pharmaceutical Co., Ltd. EV to EBITDA ratio is 10.21, with an EV/FCF ratio of 36.95.
- EV to Sales
- 3.38
- EV to EBITDA
- 10.21
- EV to Free Cash Flow
- 36.95
- EV to Operating Cash Flow
- 21.40
Balance Sheet
Lotus Pharmaceutical Co., Ltd. has TWD 6.33B in cash and marketable securities with TWD 58.45B in debt, giving a net cash position of -TWD 52.12B billion.
- Cash & Marketable Securities
- TWD 6.33B
- Total Debt
- TWD 58.45B
- Net Cash
- -TWD 52.12B
- Net Cash Per Share
- -TWD 193.01
- Tangible Book Value Per Share
- -TWD 132.69
Margins
Gross margin is 45.75%, with operating margin of 24.50%, and net profit margin of 13.22%.
- Gross Margin
- 45.75%
- Operating Margin
- 24.50%
- Pretax Margin
- 17.08%
- Net Profit Margin
- 13.22%
- EBITDA Margin
- 33.13%
- EBIT Margin
- 25.81%
Analyst Forecast
The average price target for Lotus Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 48.98%
- EPS Growth Forecast
- -21.95%
